The Guardians of the Genome Need Permission to Act, and NAD+ Is the Key
Seven enzymes control how your cells age, how they repair DNA, and how they regulate inflammation. All of them depend on a single resource to function. Research on this axis may be pointing to the most fundamental regulation in cell biology.
Biological System: Mitochondrial Energy System | Compound: NAD+ (Nicotinamide Adenine Dinucleotide) | Focus of this article: the NAD+/sirtuin axis, SIRT1-7 as NAD+-dependent regulators and the implications for cellular longevity research
In 2000, the biologist David Sinclair and his collaborators published a paper in Nature that changed the course of an entire area of biology: they demonstrated that the activation of a protein called Sir2, the ancestor of the sirtuins in mammals, was capable of extending the life of yeast. And that this activation depended critically on NAD+ levels.
Two years later, it became a cover story in Scientific American. A decade later, there were laboratories worldwide investigating the sirtuins as possible modulators of aging. Today, seven enzymes are mapped in humans, SIRT1 to SIRT7, each in a different cellular compartment, each with a set of specific functions. And all of them share an essential characteristic: they need NAD+ as a substrate to function.
Not as a cofactor that binds and stays. As a fuel that is consumed with each reaction. This means sirtuin activity is directly limited by NAD+ availability. And if NAD+ levels fall, as the evidence suggests occurs with aging, the regulatory capacity of the sirtuins falls along with it.
“The sirtuins are not enzymes with a single function. They are a regulatory system that connects the cell’s energy state, measured by available NAD+, to decisions about gene expression, repair, and survival.
The seven, and what each regulates
| SIRT1 (nuclear) | Deacetylates PGC-1α (mitochondrial biogenesis), FOXO (oxidative-stress resistance), p53 (apoptotic regulation), and NF-κB (inflammatory response). Considered the sirtuin of greatest systemic relevance in metabolic regulation. When NAD+ falls, SIRT1 is the first to feel it. |
| SIRT3 (mitochondrial) | Activates respiratory-chain enzymes and MnSOD (mitochondrial superoxide dismutase). Investigated as a regulator of mitochondrial antioxidant capacity and oxidative-metabolism efficiency. Operates inside the mitochondrion, exactly where NAD+ is most critical. |
| SIRT6 (nuclear) | Regulates telomere maintenance, double-strand DNA-break repair, and glucose metabolism via histone deacetylation. Mouse studies show life extension with SIRT6 overexpression. Connects telomere biology directly to NAD+ availability. |
| SIRT4/5 (mitochondrial) | SIRT4 regulates glutamine metabolism and the DNA-damage response. SIRT5 modifies fatty-acid metabolism and ammonia detoxification. Both investigated in mitochondrial energy-metabolism contexts. NAD+-dependent. |
| SIRT2 (cytoplasmic) | Investigated in cell-cycle control, neuronal differentiation, and proteotoxic-stress response. Role in neuroprotection under investigation; NAD+-dependence mechanisms under study. |
| SIRT7 (nuclear/nucleolus) | Regulates transcription of ribosomal genes and the DNA-damage response. Investigated in genomic stability and cellular progression. Studies suggest a role in stem-cell maintenance; connection with NAD+ homeostasis under investigation. |
“If there is an axis in cellular aging biology where multiple systems converge on a single control point, that axis is NAD+/sirtuins. The depth of that convergence is what makes research in this area so fast-moving.
The axis that connects energy to genetic information
One of the most provocative ideas to emerge from sirtuin research is the hypothesis that NAD+ functions as a sensor of the cell’s energy state, and that the sirtuins translate that signal into epigenetic decisions.
When NAD+ is high, the sirtuins are active: the genome is being regulated, inflammation is controlled, the mitochondria are renewing. When NAD+ falls, through reduced production, competition from PARPs, degradation by CD38, the sirtuins reduce their activity. And the decisions they would make stop being made.
This connects energy metabolism, the domain of the mitochondria, directly to gene expression and cellular aging. The cell uses NAD+ as information: “do we have enough resources for maintenance and repair?” When the answer is no, the maintenance program is reduced. Research is investigating whether this mechanism is reversible, and under what conditions.
Bhasin and colleagues of Harvard Medical School, the University of Colorado, and the University of Pennsylvania, in a review published in Endocrine Reviews in 2023, synthesized the state of this research: the biochemical engagement, the elevation of NAD+ levels by precursors, is consistently demonstrated. The functional translation into relevant clinical outcomes still requires larger and longer trials. But the mechanisms that justify this investigation are solidly mapped.
“The hypothesis is simple in structure: if NAD+ is the regulator of sirtuin activity, and if the sirtuins regulate fundamental processes of aging, then maintaining or restoring NAD+ may modulate those processes. That hypothesis is being actively tested, and the preclinical data are consistently promising.
Why SIRT1/PGC-1α is the most studied link
Among all the connections of the NAD+/sirtuin axis, the SIRT1/PGC-1α relationship has drawn special attention, for a clear structural reason.
PGC-1α is the “master regulator” of mitochondrial biogenesis: when active, it instructs the cell to produce more mitochondria, more efficient ones. It is the cell’s adaptive response to increased energy demand, and to the process of renewing mitochondria that age or suffer damage.
PGC-1α is activated by deacetylation by SIRT1. And SIRT1 needs NAD+ to deacetylate. This creates a direct chain: available NAD+ → active SIRT1 → deacetylated PGC-1α → mitochondrial biogenesis. Break any link in that chain and mitochondrial renewal diminishes.
In murine models, studies demonstrated that this chain is functional: the restoration of NAD+ in animals with age-related decline was accompanied by increased SIRT1 activity, PGC-1α deacetylation, and improvement in mitochondrial parameters. Zhang and colleagues, in a paper published in Science in 2016, showed that NAD+ supplementation improved mitochondrial function, stem-cell function, and lifespan in mice.
The question that human clinical trials are trying to answer, whether this chain functions with the same consistency in human populations, across different ages and conditions, is what keeps this area at the top of the longevity research agenda.
Connection within the AXION portfolio. SLU-PP-332 directly activates ERRα/γ, which share PGC-1α as a coactivator downstream of SIRT1. MOTS-c activates AMPK, which stimulates NAMPT, the enzyme that regenerates NAD+ to fuel the sirtuins. Epithalon connects via SIRT6 and telomere maintenance. The AXION Mitochondrial Energy System is built around distinct points of entry into the same regulatory axis, with NAD+ as the central node.
What research has not yet answered, and why it matters
Scientific honesty requires acknowledging that the NAD+/sirtuin axis, though mapped with increasing precision, still holds fundamental open questions.
The principal one is causality. We know that NAD+ and sirtuin activity fall with aging, and that multiple negative processes correlate with that fall. But the causal relationship, whether restoring NAD+ reverses or slows those processes in humans, with what magnitude, under what conditions, is still being established by the clinical trials underway.
The second question is specificity. The sirtuins regulate dozens of proteins in multiple cellular compartments. When we stimulate them through NAD+, which pathways are most affected? In which tissues? In what temporal sequence? The precision that precision medicine will demand of this research is still being built.
And the third is timing. If the decline begins decades before any clinical manifestation, what is the most relevant investigative window? This is a question the epidemiology of aging is trying to answer, and that will shape the next large clinical trials in the area.
What makes NAD+/sirtuins one of the most promising frontiers of aging biology is not that all the questions are answered. It is that the right questions are being asked, with better tools than ever, and with a body of preclinical evidence that fully justifies the clinical investigation now accelerating.
